Prognostic significance of immunological parameters in patients with esophageal cancer

Hepato-Gastroenterology

Volumn 43, Issue 9, 1996, Pages 501-509

  Tsutsui, Shinichi ^a   Sonoda, Kozo ^a   Sumiyoshi, Kouhei ^a   Kitamura, Kaoru ^a   Toh, Yasushi ^a   Kitamura, Masayuki ^a   Kuwano, Hiroyuki ^a   Sugimachi, Keizo ^a   Okamura, Seiichi ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Esophageal cancer; Lymphocyte subset; Natural killer cell activity; PHA response

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER SURVIVAL; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; IMMUNITY; IMMUNOLOGICAL PARAMETERS; IMMUNOSURVEILLANCE; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; SURVIVAL RATE;

CD4-CD8 RATIO; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYTOHEMAGGLUTININS; PROGNOSIS; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 0029951592     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Collard JM, Otte JB, Reynaert MS, et al. Extensive lymph node clearance for cancer of the esophagus or cardia: Merits and limits in reference to 5-year absolute survival. Hepato-Gastroenterol 1995;42:619-627.
2. Freitas D, Gouveia H, Sofia C., Cabral JP, Donato A. Endoscopic Nd-YAG laser therapy as palliation treatment for esophageal and cardial cancer. Hepato-Gastroenterol 1995;42:633-637.
3. Tranberg KG, Stael von Holstein C, Ivancev K, Cwikiel W, Lunderquist A. The YAG laser and wallstent endoprosthesis for palliation of cancer in the esophagus or gastric cardia. Hepato- Gastroenterol 1995;42:139-144.
4. Sugimachi K, Matsuoka H, Ohno S, Mori M, Kuwano H. Multivariate approach for assessing the prognosis of clinical oesophageal carcinoma. Br J Surg 1988;75:1115-8.
5. Matsuura H, Sugimachi K, Ueo H, Kuwano H, Koga Y, Okamura T. Malignant potentiality of squamous cell carcinoma of the esophagus predictable by DNA analysis. Cancer 1986;57: 1810-14.
6. Menke-Pluymers MBE, Hop WCJ, Tilanus HW. DNA ploidy as a prognostic factor for patients with an adenocarcinoma in Barrett's esophagus. Hepato-Gastroenterol 1995;42:786-788.
7. Yoshino K, Endo M, Nura S, Ishikawa N. Surgery for synchronous double cancer in the hypopharynx and thoracic esophagus. Hepato-Gastroenterol 1995;42:275-278.
8. Haffejee AA, Angorn IB. Nutritional status and the nonspecific cellular and humoral immune response in esophageal carcinoma. Ann Surg 1979;189:475-9.
9. Lozac'h P, Corbeau P, Zabbe C, Charles JF, Youinou P. Peripheral blood and tumor-infiltrating mononuclear cell analysis in esophagus and head and neck cancer. Med Oncol Tumor Pharmacother 1987;4:7-10.
10. Reinherz EL, Kung PC, Golstein G, Schlossman SF. Separation of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci U.S.A. 1979;76:4061-5.
11. Herberman RB, Ortald JR. Natural killer cells: Their role in defense against disease. Science 1981;214:24-30.
12. Talmadge JE, Meyers KM, Prieur DJ, et al. Role of NK cells in tumor growth and metastases in beige mice. Nature 1980;284: 622-4.
13. Yamamoto M, Fujii K. Optimal locoregional immunochemotherapy alter tumor-mass reduction for advanced hepatocellular carcinoma. Hepato-Gastroenterol 1995; 42:567-577.
14. Tsutsui S, Morita M, Kuwano H, Matsuda H, Mori M, Okamura S, Sugimachi K. Influence of preoperative treatment and surgical operation on immune function of patients with esophageal carcinoma. J Surg Oncol 1992;49:176-81.
15. Eilber FR, Morton DL. Impaired immunologic reactivity and recurrence following cancer surgery. Cancer 1970;25:362-7.
16. Shirabe K, Matsumata T, Maeda T, Sadanaga N, Kuwano H, Sugimachi K. A long-term surviving patient with HCC including lymphocyte infiltration. Hepato-Gastroenterol 1995;42:996-1001.
17. Wybran J, Funenberg HH. Thymus-derived rosette forming cells. N Engl J Med 1973;288:1072-3.
18. Kaszubowski PA, Husby G, Tung KSK, Williams Jr. RC. T-lymphocyte subpopulations in peripheral blood and tissue of cancer patients. Cancer Res 1980;40:4648-57.
19. Mekori T, Sher S, Robinson E. Suppression of the mitogenic response to phytohemagglutinin in malignant neoplasia: correlation with clinical stage and therapy. JNCI 1974;52:9-12.
20. Watkins SM. Cancer prognosis predicted by preoperative lymphocyte responsiveness in vitro. Br J Surg 1976;63:433-4.
21. Oka M, Hazama S, Suzuki M, Ogura Y, Kobayashi N, Suzuki T. Histological analysis of hepatocellular carcinoma treated by intraarterial combined immuno-chemotherapy. Hepato-Gastroenterol. 1995;42:561-566.
22. Dillman RO, Koziol JA, Zavanelli MI, et al. Immuno-incompetence in cancer patients. Assessment by in vitro stimulation tests and quantification of lymphocyte subpopulations. Cancer 1984;53: 1484-91.
23. McCluskey DR, Roy Ad, Abram WP, Martin WMC. T lymphcyte subsets in the peripheral blood of patients with benign and malignant breast disease. Br J Cancer 1983;47:307-309.
24. Pillai MR, Balaram P, Padmanabhan TK, Nair MK. Monoclonal antibody defined phenotypes of peripheral blood lymphocytes in cancer of the uterine cervix. AJRIM 1987;14:141-3.
25. White O, Jones DB, Cooke T, Kirkham N. Natural killer (NK) activity in peripheral blood lymphcytes of patients with benign and malignant breast disease. Br J Cancer 1982;46:611-6.
26. Salam MN, Suraiya JN, Nadkarni JJ. Natural killer and antibody-dependent cellular cytotoxicty in cervical carcinoma patients. Cancer Immunol Immunother. 1981;23:56-9.
27. Hole A, Bakke O. T-lymphocytes and the subpopulation of T-helper and T-suppressor cells measured by monoclonal antibodies (T11, T4 and T8) in relation to surgery under epidural and general anaesthesia. Acta Anaesthesiol Scand 1984;28:296-300.
28. Wiltschke Ch, Krainer M, Budinky AC, et al. Reduced mitogenic stimulation of peripheral blood mononuclear cells as a prognostic parameter for the course of breast cancer: a prospective longitudinal study. Br J Cancer 1995;71:1292-96.
29. Lennard TW, Shenton BK, Borzotta A, et al. The influence of surgical operations on components of the human immune system. Br J Surg 1985;72:771-6.
30. Toivanen A, Granberg I, Nordham E. Lymphocytic subpopulation in patients with breast cancer alter postoperative radiotherapy. Cancer 1984;54:2919-23.
31. Tichatschek E, Zielinski CC, Muller Ch, et al. Long-term influence of adjuvant therapy on natural killer cell activity in breast cancer. Cancer Immunol Immunother 1988; 27:278-82.
32. Burford-Mason A, Gyte GML, Warkins SM. Phytohaemagglutinin responsiveness of periheral lymphocytes and survival in patients with primary breast cancer. Breast Cancer Res Treat 1989;13:243-50.
33. Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 1987;122:1264-8.
34. Schantz SP, Savage HE, Racz T, Taylor DL, Sacks PG. Natural killer cells and metastases from pharyngeal carcinoma. Am J Surg 1989;158:361-6.
35. Nordman E, Lehto I, Toivanen A. Immune functions and the prognosis of patients wtih solid tumours. Cancer Immunol. Immunother. 1985;20:38-42.
36. Hersy P, Edwards A, Milton GW, McCarthy WH. No evidence for an association between natural killer cell activity and prognosis in melanoma ptients. Natl Immun Cell Growth Regul 1983/84; 3:87-94.